Potential Molecular Mechanisms for Improved Prognosis and Outcome with Neoadjuvant Chemotherapy Prior to Laparoscopical Radical Hysterectomy for Patients with Cervical Cancer

被引:10
作者
Sun, Hongzan [1 ]
Xin, Jun [1 ]
Lu, Zaiming [1 ]
Wang, Ning [2 ]
Liu, Ning [2 ]
Guo, Qiyong [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Radiol, Shenyang 110004, Liaoning, Peoples R China
[2] China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, Shenyang 110004, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
Cervical cancer; Neoadjuvant chemotherapy (NAC); miRNAs; miR-34a; miR-605; p53; E2F; Mdm2; Cisplatin; Paclitaxel; Carboplatin; ERK1/2; TAB1; GYNECOLOGIC-ONCOLOGY-GROUP; SQUAMOUS-CELL CARCINOMA; SIGNAL-REGULATED KINASE; ADJUVANT CHEMOTHERAPY; ANTICANCER DRUGS; RANDOMIZED TRIAL; GENE-EXPRESSION; STAGE-I; CISPLATIN; P53;
D O I
10.1159/000356590
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: The p53:miR-34a:E2F positive feed-forward loop and the p53:miR-605:Mdm2 positive feed-back loop have been identified to be crucial oncogenesis/tumor suppressor-regulating signaling pathways. In this study, we sought to examine the hypothesis that neoadjuvant chemotherapy (NAC) is a better approach with improved prognosis and outcomes after laparoscopical radical hysterectomy (LRH) on patients with cervical cancer and to elucidate the potential roles of the p53:miR-34a:E2F1 and the p53: miR-605: Mdm2 signaling pathways in this therapy. Methods: Twenty-one patients with stage IIB cervical cancer were recruited to this study and they were randomly divided into two groups: LRH (n=10) and NAC+LRH (n=11) groups. The NAC+LRH group consisted of 4 cycles of cisplatin, paclitaxel and carbo-platin. Complication rates and NAC outcomes (tumor size changes, 2-year disease-free survival rate, and 2-year overall survival rate) were compared between the two groups. Expression of p53, Mdm2, E2F1, miR-34a, and miR-605 at mRNA and protein levels from the tumor tissues was analyzed. Results: We observed that the diameter of tumors following chemotherapy was substantially smaller in the NAC+LRH patients than in LRH patients. No recurrence or metastasis after surgery was observed in the NAC+LRH patients, whereas 2 out of 10 LRH patients had recurrences and 1 had metastasis. The 2-year disease-free and overall survival rates were apparently higher in the NAC+LRH group than in the LRH group. Furthermore, molecular biology analyses revealed that the protein and mRNA levels of p53 were both markedly increased in patients who received NAC than those who did not, and oppositely, the levels of E2F1 and Mdm2 were significantly lower in the NAC+LRH patients than in the LRH patients. The levels of miR-34a and miR-605 were considerably higher with NAC relative to without NAC. Among the three anti-cancer drugs included in NAC, cisplatin was found to be the main component that caused increases in p53 protein levels, miR-34a and miR-605 miRNA levels, and decreases in Mdm2 and E2F1 protein levels. Furthermore, ERK1/2 inhibitor U0126 or TAB1 siRNA mitigated these changes induced by cisplatin. Conclusion: These findings not only indicate NAC as a rational approach for better treatment of cervical cancer with improved therapeutic outcomes, due partly to the ability of cisplatin to promote the p53:miR-34a: E2F1 positive feed-forward loop and the p53:miR-605:Mdm2 positive feedback loop. Copyright (C) 2013 S. Karger AG, Basel
引用
收藏
页码:1528 / 1540
页数:13
相关论文
共 49 条
  • [1] Evolving a strategic approach to cervical cancer control in Africa
    Adewole, IF
    Benedet, JL
    Crain, BT
    Follen, M
    [J]. GYNECOLOGIC ONCOLOGY, 2005, 99 (03) : S209 - S212
  • [2] ALBERTS DS, 1991, SEMIN ONCOL, V18, P11
  • [3] PHASE-II RANDOMIZED TRIAL OF CISPLATIN CHEMOTHERAPY REGIMENS IN THE TREATMENT OF RECURRENT OR METASTATIC SQUAMOUS-CELL CANCER OF THE CERVIX - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    ALBERTS, DS
    KRONMAL, R
    BAKER, LH
    STOCKNOVACK, DL
    SURWIT, EA
    BOUTSELIS, JG
    HANNIGAN, EV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (11) : 1791 - 1795
  • [4] Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma
    AlSaleh, E
    Hoskins, PJ
    Pike, JA
    Swenerton, KD
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 64 (03) : 468 - 472
  • [5] [Anonymous], BERECK HACKERS GYNEC
  • [6] Worldwide burden of cervical cancer in 2008
    Arbyn, M.
    Castellsague, X.
    de Sanjose, S.
    Bruni, L.
    Saraiya, M.
    Bray, F.
    Ferlay, J.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (12) : 2675 - 2686
  • [7] Aetiology, pathogenesis, and pathology of cervical neoplasia
    Arends, MJ
    Buckley, CH
    Wells, M
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (02) : 96 - 103
  • [8] MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY
    BARAK, Y
    JUVEN, T
    HAFFNER, R
    OREN, M
    [J]. EMBO JOURNAL, 1993, 12 (02) : 461 - 468
  • [9] Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209
  • [10] A PHASE-II EVALUATION OF CISPLATIN AND 5-FLUOROURACIL IN PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
    BONOMI, P
    BLESSING, J
    BALL, H
    HANJANI, P
    DISAIA, PJ
    [J]. GYNECOLOGIC ONCOLOGY, 1989, 34 (03) : 357 - 359